Literature DB >> 23009938

Myeloproliferative neoplasm animal models.

Ann Mullally1, Steven W Lane, Kristina Brumme, Benjamin L Ebert.   

Abstract

Myeloproliferative neoplasm (MPN) animal models accurately re-capitulate human disease in mice and have been an important tool for the study of MPN biology and therapy. Transplantation of BCR-ABL transduced bone marrow into irradiated syngeneic mice established the field of MPN animal modeling. Genetically engineered MPN animal models have enabled detailed characterization of the effects of specific MPN-associated genetic abnormalities on hematopoietic stem and progenitor cells (HSPCs). Xenograft models have allowed the study of primary human MPN-propagating cells in vivo. JAK2V617F, the most common molecular abnormality in BCR-ABL negative MPN, has been extensively studied using retroviral, transgenic, knock-in and xenograft models.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23009938      PMCID: PMC3459181          DOI: 10.1016/j.hoc.2012.07.007

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  86 in total

1.  Lnk constrains myeloproliferative diseases in mice.

Authors:  Alexey Bersenev; Chao Wu; Joanna Balcerek; Jiang Jing; Mondira Kundu; Gerd A Blobel; Kudakwashe R Chikwava; Wei Tong
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

Authors:  Ross L Levine; Claude Belisle; Martha Wadleigh; David Zahrieh; Stephanie Lee; Pierre Chagnon; D Gary Gilliland; Lambert Busque
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

3.  Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.

Authors:  Bin Zhang; Adam C Strauss; Su Chu; Min Li; Yinwei Ho; Keh-Dong Shiang; David S Snyder; Claudia S Huettner; Leonard Shultz; Tessa Holyoake; Ravi Bhatia
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

4.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Authors:  Mirle Schemionek; Christian Elling; Ulrich Steidl; Nicole Bäumer; Ashley Hamilton; Tilmann Spieker; Joachim R Göthert; Martin Stehling; Amy Wagers; Claudia S Huettner; Daniel G Tenen; Lara Tickenbrock; Wolfgang E Berdel; Hubert Serve; Tessa L Holyoake; Carsten Müller-Tidow; Steffen Koschmieder
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

5.  The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms.

Authors:  Sool Yeon Cho; Mingjiang Xu; John Roboz; Min Lu; John Mascarenhas; Ronald Hoffman
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

6.  Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

Authors:  Priya Koppikar; Omar Abdel-Wahab; Cyrus Hedvat; Sachie Marubayashi; Jay Patel; Aviva Goel; Nicole Kucine; Jeffrey R Gardner; Andrew P Combs; Kris Vaddi; Patrick J Haley; Timothy C Burn; Mark Rupar; Jacqueline F Bromberg; Mark L Heaney; Elisa de Stanchina; Jordan S Fridman; Ross L Levine
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

7.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Authors:  Hajime Akada; Dongqing Yan; Haiying Zou; Steven Fiering; Robert E Hutchison; M Golam Mohi
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

8.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Authors:  Catherine Lacout; Didier F Pisani; Micheline Tulliez; Françoise Moreau Gachelin; William Vainchenker; Jean-Luc Villeval
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

9.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Authors:  Gerlinde Wernig; Thomas Mercher; Rachel Okabe; Ross L Levine; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

10.  JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

Authors:  Mark A Dawson; Andrew J Bannister; Berthold Göttgens; Samuel D Foster; Till Bartke; Anthony R Green; Tony Kouzarides
Journal:  Nature       Date:  2009-09-27       Impact factor: 49.962

View more
  17 in total

1.  CD133 marks a stem cell population that drives human primary myelofibrosis.

Authors:  Ioanna Triviai; Thomas Stübig; Birte Niebuhr; Kais Hussein; Asterios Tsiftsoglou; Boris Fehse; Carol Stocking; Nicolaus Kröger
Journal:  Haematologica       Date:  2015-02-27       Impact factor: 9.941

Review 2.  Myeloproliferative neoplasm stem cells.

Authors:  Adam J Mead; Ann Mullally
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

3.  Sinister symbiosis: pathological hematopoietic-stromal interactions in CML.

Authors:  Ann Mullally; Benjamin L Ebert
Journal:  Cell Stem Cell       Date:  2013-09-05       Impact factor: 24.633

4.  Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm.

Authors:  Thanh Kim Nguyen; Sarah J Morse; Angela G Fleischman
Journal:  J Vis Exp       Date:  2016-12-22       Impact factor: 1.355

5.  Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology.

Authors:  Yuichi Ishikawa; Manami Maeda; Mithun Pasham; Francois Aguet; Silvia K Tacheva-Grigorova; Takeshi Masuda; Hai Yi; Sung-Uk Lee; Jian Xu; Julie Teruya-Feldstein; Maria Ericsson; Ann Mullally; John Heuser; Tom Kirchhausen; Takahiro Maeda
Journal:  Haematologica       Date:  2014-12-31       Impact factor: 9.941

6.  Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.

Authors:  Markus Bender; Silvia Giannini; Renata Grozovsky; Terese Jönsson; Hilary Christensen; Fred G Pluthero; Amy Ko; Ann Mullally; Walter H A Kahr; Karin M Hoffmeister; Hervé Falet
Journal:  Blood       Date:  2014-12-02       Impact factor: 22.113

Review 7.  Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).

Authors:  Andrew Dunbar; Abbas Nazir; Ross Levine
Journal:  Curr Protoc Pharmacol       Date:  2017-06-22

8.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Authors:  Shannon Elf; Nouran S Abdelfattah; Edwin Chen; Javier Perales-Patón; Emily A Rosen; Amy Ko; Fabian Peisker; Natalie Florescu; Silvia Giannini; Ofir Wolach; Elizabeth A Morgan; Zuzana Tothova; Julie-Aurore Losman; Rebekka K Schneider; Fatima Al-Shahrour; Ann Mullally
Journal:  Cancer Discov       Date:  2016-03-07       Impact factor: 39.397

9.  Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.

Authors:  Edwin Chen; Rebekka K Schneider; Lawrence J Breyfogle; Emily A Rosen; Luke Poveromo; Shannon Elf; Amy Ko; Kristina Brumme; Ross Levine; Benjamin L Ebert; Ann Mullally
Journal:  Blood       Date:  2014-10-03       Impact factor: 22.113

10.  Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.

Authors:  Mairi S Shepherd; Juan Li; Nicola K Wilson; Caroline A Oedekoven; Jiangbing Li; Miriam Belmonte; Juergen Fink; Janine C M Prick; Dean C Pask; Tina L Hamilton; Dirk Loeffler; Anjana Rao; Timm Schröder; Berthold Göttgens; Anthony R Green; David G Kent
Journal:  Blood       Date:  2018-07-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.